Your browser is no longer supported. Please, upgrade your browser.
Settings
QURE uniQure N.V. daily Stock Chart
QURE [NASD]
uniQure N.V.
Index- P/E- EPS (ttm)-2.96 Insider Own3.40% Shs Outstand30.76M Perf Week9.72%
Market Cap979.09M Forward P/E- EPS next Y-3.68 Insider Trans-9.10% Shs Float30.20M Perf Month53.18%
Income-81.00M PEG- EPS next Q-0.74 Inst Own62.90% Short Float3.55% Perf Quarter75.08%
Sales13.10M P/S74.74 EPS this Y-2.40% Inst Trans0.60% Short Ratio2.90 Perf Half Y165.69%
Book/sh2.86 P/B11.13 EPS next Y-14.60% ROA-46.90% Target Price31.90 Perf Year487.27%
Cash/sh5.18 P/C6.14 EPS next 5Y- ROE-174.20% 52W Range4.72 - 29.89 Perf YTD62.48%
Dividend- P/FCF- EPS past 5Y-27.90% ROI-66.10% 52W High6.49% Beta0.15
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low574.36% ATR1.66
Employees202 Current Ratio8.50 Sales Q/Q-63.90% Oper. Margin- RSI (14)75.40 Volatility4.28% 7.00%
OptionableYes Debt/Eq0.23 EPS Q/Q-53.50% Profit Margin- Rel Volume1.15 Prev Close29.80
ShortableYes LT Debt/Eq0.22 EarningsMar 21 BMO Payout- Avg Volume369.77K Price31.83
Recom1.70 SMA2028.12% SMA5031.96% SMA200104.46% Volume422,396 Change6.81%
Jan-04-18Initiated Janney Buy $25
Dec-01-17Initiated H.C. Wainwright Buy $28
Nov-07-17Initiated Evercore ISI Outperform $22
Oct-20-17Reiterated Leerink Partners Outperform $17 → $19
Dec-06-16Reiterated WallachBeth Buy $27 → $15
Nov-22-16Downgrade Jefferies Buy → Hold
Nov-16-16Downgrade Piper Jaffray Overweight → Neutral
Aug-04-16Resumed H.C. Wainwright Buy $21
Jun-15-16Reiterated WallachBeth Buy $60 → $35
Feb-24-16Resumed H.C. Wainwright Buy $30
Dec-01-15Reiterated WallachBeth Buy $33 → $60
Nov-30-15Resumed ROTH Capital Buy $37
Oct-01-15Reiterated Chardan Capital Markets Buy $35 → $40
Sep-21-15Reiterated Oppenheimer Outperform $47 → $50
Aug-28-15Reiterated WallachBeth Buy $35 → $33
Aug-27-15Reiterated Chardan Capital Markets Buy $40 → $35
Aug-07-15Initiated WallachBeth Buy $35
Apr-24-15Initiated Chardan Capital Markets Buy $40
Apr-14-15Initiated ROTH Capital Buy $38
Mar-02-15Initiated H.C. Wainwright Buy $30
Apr-13-18 10:06AM  Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus Zacks
07:51AM  How Do Analysts See uniQure NV. (NASDAQ:QURE) Performing In The Next Couple Of Years? Simply Wall St.
Apr-09-18 07:35AM  Report: Developing Opportunities within Consol Energy, 51job, MakeMyTrip, LyondellBasell Industries N.V, Golden Ocean Group, and uniQure N.V Future Expectations, Projections Moving into 2018 GlobeNewswire +16.44%
Mar-20-18 11:39AM  Janney: Buy The Dip In Uniqure Benzinga +6.64%
Mar-16-18 08:25AM  Report: Developing Opportunities within Itau Unibanco Banco Holding SA, NantHealth, Southern First Bancshares, uniQure N.V., Ascendis Pharma A/S, and National General Future Expectations, Projections Moving into 2018 GlobeNewswire
Mar-14-18 07:00AM  uniQure Announces 2017 Financial Results and Recent Company Progress GlobeNewswire -10.95%
Feb-27-18 07:00AM  uniQure to Participate in Multiple Conferences in March GlobeNewswire
Feb-01-18 07:00AM  uniQure to Participate in Multiple Conferences in February GlobeNewswire
Jan-22-18 07:00AM  uniQure Receives Orphan Medicinal Product Designation in Europe for AMT-130 in Huntingtons disease GlobeNewswire +9.56%
Jan-08-18 07:00AM  uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value GlobeNewswire -6.93%
Dec-18-17 07:00AM  uniQure Announces Publication in the Journal Blood of Clinical Data from Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B GlobeNewswire
Dec-11-17 04:01PM  uniQure Added to NASDAQ Biotechnology Index GlobeNewswire
07:41AM  UniQure shares jump 3.8% premarket on positive trial of hemophelia treatment MarketWatch
07:00AM  uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B GlobeNewswire
Dec-09-17 09:00AM  uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Nov-07-17 08:07AM  uniQure NV :QURE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-01-17 09:10AM  uniQure Announces Presentations at the 59th American Society of Hematology (ASH) Annual Meeting GlobeNewswire
07:17AM  UniQure reports 3Q loss Associated Press
07:00AM  uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress GlobeNewswire
Oct-31-17 04:02PM  uniQure Announces Multiple Company Presentations at Upcoming November Conferences GlobeNewswire
Oct-27-17 04:03PM  uniQure Announces Closing of its Public Offering GlobeNewswire
Oct-24-17 08:14PM  uniQure Announces Pricing of its Public Offering GlobeNewswire
Oct-23-17 04:06PM  uniQure Announces Proposed Public Offering GlobeNewswire
Oct-21-17 10:32AM  3 Healthcare Stocks That Soared This Week: Are They Buys? Motley Fool
Oct-20-17 03:00PM  Why uniQure N.V. Stock Is Hopping Today Motley Fool +27.11%
Oct-19-17 03:28PM  Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3 SmarterAnalyst +60.08%
12:54PM  Why UniQure (QURE) Stock is Skyrocketing Today Zacks
07:05AM  uniQure Strengthens Intellectual Property Portfolio with Acquisition of Patent Family Providing Broad Protection of the Hyperactive Padua Variant of Factor IX (FIX-Padua) GlobeNewswire
07:00AM  uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 GlobeNewswire
Oct-18-17 07:00AM  uniQure Presents New Preclinical Data on AMT-130 in Huntingtons Disease at the ESGCT 25th Anniversary Congress in Berlin GlobeNewswire -18.85%
Oct-17-17 08:39AM  uniQure (QURE) in Focus: Stock Moves 11.9% Higher Zacks
Oct-06-17 07:00AM  uniQure Announces FDA Orphan Drug Designation for AMT-130 in Huntingtons disease GlobeNewswire
Oct-02-17 07:00AM  uniQure Announces Company Presentations at Upcoming October Conferences GlobeNewswire +8.23%
Sep-21-17 09:34PM  Should You Buy uniQure NV (QURE)? Simply Wall St. +12.01%
Sep-20-17 12:48PM  uniQure NV :QURE-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017 Capital Cube
Aug-24-17 07:00AM  uniQure Announces Company Participation at Citi Healthcare Conference GlobeNewswire
Aug-08-17 05:22PM  UniQure reports 2Q loss Associated Press
07:00AM  uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress GlobeNewswire
Aug-07-17 07:00AM  uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors GlobeNewswire
Jul-31-17 07:00AM  uniQure Reacquires Development and Commercialization Rights for its Gene Therapy Candidate in Hemophilia B GlobeNewswire
Jul-21-17 07:00AM  uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program GlobeNewswire
Jul-20-17 08:20AM  uniQure N.V. (QURE) Shows Strength: Stock Moves 9.1% Higher Zacks +6.15%
Jul-18-17 07:00AM  uniQure Expands Intellectual Property Portfolio with Newly Issued Patent Providing Broad Protection of Insect Cell-Based AAV Manufacturing GlobeNewswire +10.34%
Jul-11-17 06:30AM  uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies GlobeNewswire
Jul-10-17 12:46PM  uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B GlobeNewswire
Jul-07-17 05:08PM  A Barrage Of Biotech Updates Expected At ISTH Meeting Benzinga
Jun-23-17 07:00AM  uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis (ISTH) Congress GlobeNewswire
Jun-15-17 07:00AM  uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies GlobeNewswire
Jun-06-17 07:00AM  uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer GlobeNewswire
Jun-02-17 10:20AM  uniQure NV :QURE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 07:00AM  uniQure Announces Company Presentation at Jefferies Healthcare Conference GlobeNewswire
May-11-17 07:00AM  uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates GlobeNewswire
May-10-17 07:00AM  uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates GlobeNewswire
May-09-17 07:00AM  uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress GlobeNewswire
May-01-17 07:00AM  uniQure Announces Company Presentations at Upcoming May Conferences GlobeNewswire
Apr-26-17 07:00AM  uniQure Presents New Preclinical Data on AMT-130 in Huntingtons Disease at CHDIs 12th Annual Huntingtons Disease Therapeutics Conference GlobeNewswire +5.74%
Apr-25-17 07:05AM  uniQure Receives European Medicines Agency Priority Medicines (PRIME) Designation for AMT-060 in Hemophilia B GlobeNewswire
Apr-24-17 04:05PM  uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) GlobeNewswire -6.81%
Apr-20-17 11:05AM  Biotech firm pulls pioneering gene therapy due to no demand Reuters
07:00AM  uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe GlobeNewswire
Apr-04-17 07:42AM  uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System GlobeNewswire
07:42AM  uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System
Apr-03-17 07:00AM  uniQure Announces Presentations at Upcoming April Conferences GlobeNewswire
Mar-21-17 01:04PM  UNIQURE N.V. Financials
Mar-15-17 09:18AM  UNIQURE N.V. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
07:54AM  UNIQURE N.V. Files SEC form 10-K, Annual Report
07:00AM  uniQure Announces 2016 Financial Results and Provides Update on Company Progress GlobeNewswire
Mar-03-17 07:00AM  uniQure Receives 2017 Frost & Sullivan Manufacturing Leadership Award GlobeNewswire
Mar-01-17 07:00AM  uniQure Announces Presentations at Upcoming March Conferences GlobeNewswire
Feb-14-17 10:31AM  Can The Uptrend Continue for uniQure N.V. (QURE)? Zacks
10:31AM  Can The Uptrend Continue for uniQure N.V. (QURE)?
Feb-10-17 03:32AM  Will Uniqure (QURE) Continue to Surge Higher? Zacks +5.95%
03:32AM  Will Uniqure (QURE) Continue to Surge Higher?
Feb-06-17 07:00AM  uniQure Announces Presentations at Upcoming February Conferences GlobeNewswire
Jan-30-17 02:54PM  UNIQURE N.V. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B GlobeNewswire
Jan-25-17 07:00AM  uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs GlobeNewswire
Jan-09-17 07:00AM  uniQure Outlines Key Initiatives for 2017 and Vision for 2018 GlobeNewswire
Dec-29-16 08:54AM  uniQure (QURE): Strong Industry, Solid Earnings Estimate Revisions
Dec-19-16 07:00AM  uniQure Appoints Matthew Kapusta as Chief Executive Officer GlobeNewswire
Dec-05-16 01:11PM  Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting
11:33AM  Heres Why We Think Theres Opportunity In Uniqure NV (QURE) at Insider Monkey
Dec-03-16 03:52PM  uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B GlobeNewswire
01:04PM  Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
Dec-02-16 07:05AM  uniQure to Present at the Genetic Rx Boston Biotech Conference at Harvard Medical School GlobeNewswire -5.18%
Nov-28-16 04:50AM  Many Billion-Dollar Biobuck Drug Deals Go Bust at Investopedia
Nov-22-16 07:25AM  uniQure downgraded by Jefferies -6.45%
07:14AM  UniQure reports 3Q loss
07:00AM  uniQure Announces Financial Results For Third Quarter 2016 and Provides Update on Company Progress GlobeNewswire
Nov-17-16 12:00PM  UniQure Sees $22M Savings on Restructuring (QURE) at Investopedia
Nov-16-16 08:15AM  Blog Coverage Biopharma Company uniQure Undertakes a Companywide Strategic Review Aimed at Increasing Shareholders Value Accesswire -8.93%
Nov-15-16 07:05AM  uniQure Completes Strategic Review to Refocus its Pipeline, Reduce Operating Costs and Deliver Long-Term Shareholder Value GlobeNewswire -6.87%
Nov-03-16 09:11AM  uniQure Announces Upcoming Presentation of Data at Annual American Society of Hematology Meeting GlobeNewswire
Sep-26-16 09:18AM  uniQure to Present at the Jefferies Gene Editing and Gene Therapy Summit in New York City GlobeNewswire
Sep-22-16 04:18PM  uniQure Announces Management and Board Changes GlobeNewswire
Sep-16-16 07:13AM  uniQure Receives NASDAQ Deficiency Letter Related to Board Composition GlobeNewswire
Aug-25-16 04:18PM  uniQure Announces Financial Results For Second Quarter 2016 and Update on Company Progress GlobeNewswire
04:13PM  UniQure reports 2Q loss
Aug-17-16 07:12AM  uniQure to Present at Upcoming Investor Conferences in September GlobeNewswire
Jul-27-16 02:27PM  uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect GlobeNewswire
uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company's principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency. The company has collaboration and license agreements with Bristol-Myers Squibb Company, 4D Molecular Therapeutics, Synpromics, and Chiesi Farmaceutici S.p.A. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kapusta Matthew CCEO, CFO, Managing DirectorMar 15Sale21.7239,169850,751439,764Mar 19 03:35 PM
Soteropoulos PaulaDirectorJan 29Sale18.532,87853,32917,914Jan 31 10:51 AM
van Deventer SanderChief Scientific OfficerJan 29Sale18.535,985110,90225,069Jan 31 10:42 AM
Astley-Sparke PhilipDirectorJan 29Sale18.536,540121,18628,252Jan 31 10:39 AM
Kaye JackDirectorJan 29Sale18.532,87853,32912,914Jan 31 10:34 AM
SCHAFFER DAVIDDirectorJan 29Sale18.532,87853,32915,314Jan 31 10:30 AM
Kapusta Matthew CCEO, CFO, Managing DirectorJan 04Sale19.8721,690431,069447,559Jan 05 04:40 PM
Garen JonathanChief Business OfficerJan 03Sale20.135,864118,02885,251Jan 03 05:52 PM
Firuta Paul EChief Commercial OfficerJan 03Sale20.135,864118,02885,251Jan 03 05:50 PM
Cantor Maria ESVP, Investor Relations & CommJan 03Sale20.135,864118,02885,251Jan 03 05:49 PM
KLEMT CHRISTIANChief Accounting OfficerJan 03Sale20.135,093102,51037,257Jan 05 04:41 PM
Petry HaraldChief Scientific OfficerJun 29Option Exercise3.5021,54775,43021,547Jun 29 05:05 PM
Petry HaraldChief Scientific OfficerJun 29Sale6.0221,547129,7090Jun 29 05:05 PM
Petry HaraldChief Scientific OfficerJun 28Option Exercise3.4927,75396,93327,753Jun 29 05:05 PM
Petry HaraldChief Scientific OfficerJun 28Sale6.0127,753166,8590Jun 29 05:05 PM
Petry HaraldChief Scientific OfficerJun 27Option Exercise3.487,70026,8047,700Jun 28 05:05 PM
Petry HaraldChief Scientific OfficerJun 27Sale6.007,70046,2150Jun 28 05:05 PM
Petry HaraldChief Scientific OfficerJun 26Option Exercise3.4358,075199,36658,075Jun 28 05:05 PM
Petry HaraldChief Scientific OfficerJun 26Sale6.0158,075349,0540Jun 28 05:05 PM
Petry HaraldChief Scientific OfficerJun 22Option Exercise3.42155531155Jun 28 05:05 PM
Petry HaraldChief Scientific OfficerJun 22Sale6.001559300Jun 28 05:05 PM